INS and insomnia measurement: The dynamic changes in insomnia symptoms further highlight the pathological specificity of metabolic diseases: the rapid exacerbation of insomnia in the early stage is directly associated with “blood glucose anxiety during the transition period of home-based management,” while the slowed progression in the middle stage is related to hypoglycemia intervention (e.g., insulin dose adjustment) and the elevation of the central fatigue threshold (25, 26).